Literature DB >> 18195175

Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study.

Deborah M Friedman1, Mimi Y Kim, Joshua A Copel, Claudine Davis, Colin K L Phoon, Julie S Glickstein, Jill P Buyon.   

Abstract

BACKGROUND: Anti-SSA/Ro-associated third-degree congenital heart block is irreversible, prompting a search for early markers and effective therapy. METHODS AND
RESULTS: One hundred twenty-seven pregnant women with anti-SSA/Ro antibodies were enrolled; 95 completed an evaluable course in 98 pregnancies. The protocol included fetal echocardiograms performed weekly from 16 to 26 weeks' gestation and biweekly from 26 to 34 weeks. PR intervals >150 ms were considered prolonged, consistent with first-degree block. Ninety-two fetuses had normal PR intervals. Neonatal lupus developed in 10 cases; 4 were neonatal lupus rash only. Three fetuses had third-degree block; none had a preceding abnormal PR interval, although in 2 fetuses >1 week elapsed between echocardiographic evaluations. Tricuspid regurgitation preceded third-degree block in 1 fetus, and an atrial echodensity preceded block in a second. Two fetuses had PR intervals >150 ms. Both were detected at or before 22 weeks, and each reversed within 1 week with 4 mg dexamethasone. The ECG of 1 additional newborn revealed a prolonged PR interval persistent at 3 years despite normal intervals throughout gestation. No first-degree block developed after a normal ECG at birth. Heart block occurred in 3 of 16 pregnancies (19%) in mothers with a previous child with congenital heart block and in 3 of 74 pregnancies (4%) in mothers without a previous child with congenital heart block or rash (P=0.067).
CONCLUSIONS: Prolongation of the PR interval was uncommon and did not precede more advanced block. There was a trend toward more congenital heart block in fetuses of women with previously affected offspring than those without previously affected offspring. Advanced block and cardiomyopathy can occur within 1 week of a normal echocardiogram without initial first-degree block. Echodensities and moderate/severe tricuspid regurgitation merit attention as early signs of injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195175     DOI: 10.1161/CIRCULATIONAHA.107.707661

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  65 in total

1.  Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus.

Authors:  Peter M Izmirly; Amit Saxena; Mimi Y Kim; Dan Wang; Sara K Sahl; Carolina Llanos; Deborah Friedman; Jill P Buyon
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

Review 2.  Fetal cardiac arrhythmia detection and in utero therapy.

Authors:  Janette F Strasburger; Ronald T Wakai
Journal:  Nat Rev Cardiol       Date:  2010-05       Impact factor: 32.419

3.  Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies.

Authors:  Ruben J Acherman; Deborah M Friedman; Jill P Buyon; Joel Schwartz; William J Castillo; Robert C Rollins; William N Evans
Journal:  Prenat Diagn       Date:  2010-08       Impact factor: 3.050

4.  Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus.

Authors:  Carolina Llanos; Deborah M Friedman; Amit Saxena; Peter M Izmirly; Chung-E Tseng; Renata Dische; Rosanna G Abellar; Marc Halushka; Robert M Clancy; Jill P Buyon
Journal:  Rheumatology (Oxford)       Date:  2012-02-03       Impact factor: 7.580

Review 5.  Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk.

Authors:  J P Buyon; R M Clancy; D M Friedman
Journal:  J Intern Med       Date:  2009-06       Impact factor: 8.989

Review 6.  Prenatal evaluation and management of fetuses exposed to Anti-SSA/Ro antibodies.

Authors:  Anita Krishnan; Jodi I Pike; Mary T Donofrio
Journal:  Pediatr Cardiol       Date:  2012-05-22       Impact factor: 1.655

Review 7.  Magnetocardiography for fetal arrhythmias.

Authors:  Janette F Strasburger; Bageshree Cheulkar; Ronald T Wakai
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

Review 8.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

9.  Outcome of prenatally diagnosed isolated congenital complete atrioventricular block treated with transplacental betamethasone or ritodrine therapy.

Authors:  Taiyu Hayashi; Masahide Kaneko; Ki-Sung Kim; Yoshihiko Eryu; Takahiro Shindo; Takayoshi Isoda; Atsuko Murashima; Yushi Ito; Haruhiko Sago
Journal:  Pediatr Cardiol       Date:  2008-07-26       Impact factor: 1.655

Review 10.  Management of pregnancy in systemic lupus erythematosus.

Authors:  Aisha Lateef; Michelle Petri
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.